The evidence standard the Centers for Medicare & Medicaid Services (CMS) used to approve Medicare coverage of a stool DNA colorectal cancer (CRC) screening test — under a new joint approval process with the U.S. Food and Drug Administration (FDA) — should be applied to CT colonography (virtual colonoscopy) and other CRC screening exams according to the American College of Radiology (ACR). In a new letter to CMS, ACR urged coverage criteria be transparent and consistently applied.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now